Description:

Z1041: Study Drug Completion - Trastuzumab (SDCT) NCT00513292 Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=20FDDD9E-AEC2-1D91-E044-0003BA3F9857

Link:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=20FDDD9E-AEC2-1D91-E044-0003BA3F9857
Keywords:
  1. 8/26/12 8/26/12 -
  2. 1/9/15 1/9/15 - Martin Dugas
  3. 6/27/15 6/27/15 -
Uploaded on:

June 27, 2015

DOI:
To request one please log in.
License :
Creative Commons BY-NC 3.0 Legacy
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Z1041: Study Drug Completion - Trastuzumab (SDCT) NCT00513292

No Instruction available.

  1. StudyEvent: Z1041: Study Drug Completion - Trastuzumab (SDCT)
    1. No Instruction available.
Header Module
Visit
Study Drug Assessment
This form was completed based on information from
Were there any dose modifications or additions/omissions to protocol treatment?
Dose Modification Reason
Did the patient receive RT during this reporting period
Did the patient receive any hormone therapy during this reporting period?

Similar models

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial